• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Set to Join S&P SmallCap 600

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    May 1, 2023

    S&P SmallCap 600

    Addition

    Cytek Biosciences

    CTKB

    Health Care



    S&P SmallCap 600

    Deletion

    Cardiovascular Systems

    CSII

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/cytek-biosciences-set-to-join-sp-smallcap-600-301807529.html

    SOURCE S&P Dow Jones Indices

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $CSII
    $CTKB
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    More analyst ratings

    $ABT
    $CSII
    $CTKB
    $SPGI
    SEC Filings

    View All

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/16/25 4:05:25 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    12/12/25 4:10:48 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/4/25 4:16:26 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

    First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heartNew delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babiesA PDA requiring treatment is present in approximately 20% of premature infants1ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder. The new delivery system is designed specifically to treat premature babies (some weighing as l

    12/18/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Launches StepForward: $10 Million Initiative Preparing Global Youth for AI-Enabled Futures

    Three-year philanthropic program will award grants to nonprofits focused on workforce readiness and AI education NEW YORK, Dec. 17, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the launch of StepForward, a new philanthropic initiative aimed at equipping the next generation with the skills needed to succeed in an AI-enabled workforce. Through StepForward, S&P Global and the S&P Global Foundation will invest $10 million over the next three years to support organizations delivering innovative workforce development programs for youth. The initiative will also lever

    12/17/25 2:30:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP AND GROUP PRESIDENT Salvadori Daniel Gesua Sive gifted 1,536 units of Common shares without par value, decreasing direct ownership by 1% to 132,233 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    12/12/25 5:04:36 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior Vice President Shroff Eric sold $203,043 worth of Common shares without par value (1,586 units at $128.02), decreasing direct ownership by 5% to 30,384 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    11/25/25 4:17:30 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 21,031 shares and covered exercise/tax liability with 5,123 shares, increasing direct ownership by 0.26% to 6,073,327 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    11/20/25 7:09:01 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    6/3/25 5:39:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    S&P Global Adds Hubert Joly to its Board of Directors

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026. Mr. Joly is the former Chair and Chief Executive Officer at Best Buy and is now a senior lecturer at Harvard Business School. Earlier in his career, Mr. Joly served as President and CEO of Carlson, a global hospitality and travel company. In addition to his teaching post at Harvard, Mr. Joly is a member of the Board of Directors of Johnson & Johnson and was until recently on the Board of

    12/16/25 8:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Mobility Business Chief Financial Officer

    Matt Calderone, outgoing CFO of Booz Allen, named new CFO of Mobility and will lead the finance function of the standalone company NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Matt Calderone as Chief Financial Officer (CFO) of the Mobility business, joining the company by March 1, 2026. Mr. Calderone will serve as the CFO of the standalone public company through its planned separation from S&P Global and will oversee all aspects of the company's Finance function. He will report to Mr. Bill Eager, President of S&P Global Mobility, and CEO-designate of the future standalone company.

    12/16/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Corebridge Financial Inc. (NYSE:CRBG) will replace Allete Inc. (NYSE:ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 17, 2025 S&P MidCap 400 Addition Corebridge Financial CRBG Financials Dec 17, 2025 S&P MidCap 400 Deletion Allete ALE Utilities ABOUT S&P DOW JONES INDICES S

    12/12/25 5:51:00 PM ET
    $ALE
    $CRBG
    $SPGI
    Power Generation
    Utilities
    Life Insurance
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    S&P Global Completes $1.8 Billion Acquisition of With Intelligence, Strengthening its Position as a Leader in Private Markets Data & Analytics

    Combination unlocks new market opportunities and cements S&P Global as one of the most comprehensive providers of private markets intelligence NEW YORK, Nov. 25, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the successful completion of its acquisition of With Intelligence, a leading source of private markets data, insights and analytics for $1.8 billion, from a group led by majority investor Motive Partners, a private investment firm focused exclusively on financial and tech-enabled business services companies. First announced in October, the deal significantly

    11/25/25 1:25:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance